Immune check point inhibitors （ICPi） have shown activity not only in malignant melanoma but also in lung cancer, renal cell carcinoma, urothelial carcinoma and so on. With regard to head and neck cancer （HNC）, ICPi improves survival for platinum refractory HNC and many clinical trials of ICPi for HNC are ongoing. In Japan, nivolumab, one of the PD-1 antibodies, has been approved since March 2017 and can now be used in clinical practice. On the other hand, ICPi may cause immune related adverse events （irAE）, sometimes resulting in severe sequelae. Thus, medical oncologists should closely support and collaborate with head and neck surgeons and oral and maxillofacial surgeons. In order to promote such collaboration, the Japanese Society of Medical Oncology （JSMO） has established the Head and Neck Cancer Collaborative program.